A managerial approach to research and development cost-effectiveness evaluation

1990 ◽  
Vol 37 (2) ◽  
pp. 134-138 ◽  
Author(s):  
Y. Kuwahara ◽  
Y. Takeda
Keyword(s):  
Cost Effectiveness ◽  
Research And Development ◽  
Effectiveness Evaluation ◽  
Development Cost

A cost-effectiveness evaluation of newborn hemoglobinopathy screening in Alaska

1996 ◽  
Author(s):  
Bradford D. Gessner ◽  
Steven M. Teutsch ◽  
Phaedra A. Shaffer
Keyword(s):  
Cost Effectiveness ◽  
Effectiveness Evaluation

scholarly journals Correction to: Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Chun-Yi Lu ◽  
Ching-Hu Chung ◽  
Li-Min Huang ◽  
Eliza Kruger ◽  
Seng-Chuen Tan ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Haemophilus Influenzae ◽  
Conjugate Vaccine ◽  
Effectiveness Evaluation

An amendment to this paper has been published and can be accessed via the original article.

scholarly journals 49P Cost-Effectiveness Evaluation of The 21-Gene Breast Cancer Test in France

2012 ◽  
Vol 23 ◽  
pp. ii29
Author(s):  
R. Rouzier ◽  
E. Chereau ◽  
E. Laas ◽  
A. Genin ◽  
S. Bendifallah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Effectiveness Evaluation

A Pharmacoeconomic Analysis of Phosphate Binders Cost-Effectiveness in the RISCAVID Study

2015 ◽  
Vol 39 (1-3) ◽  
pp. 174-180 ◽  
Author(s):  
Vincenzo Panichi ◽  
Alberto Rosati ◽  
Adriana Di Giorgio ◽  
Alessia Scatena ◽  
Roberto Bigazzi ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Pharmacoeconomic Analysis ◽  
Phosphate Binders ◽  
Effectiveness Evaluation ◽  
C Reactive Protein ◽  
Stroke Incidence ◽  
Mortality And Morbidity ◽  
Reactive Protein ◽  
The Cost ◽  
Hospital Days

Background: A pharmacoeconomic analysis of the RISCAVID database aimed at assessing the cost effectiveness of phosphate binders in preventing CV mortality and morbidity over 7 years was performed. Methods: Morbid or fatal events occurring in 750 chronic HD patients were recorded. Statistical analysis evaluated the distribution of variables and the effect of sevelamer on survival. A cost-effectiveness evaluation was performed using a probabilistic model based on a Markov chain. Results: Multivariate analysis showed that treatment with sevelamer was associated with a reduced stroke incidence by 52% (p = 0.04) and reduced levels of C-reactive protein (p < 0.01). Cost-effectiveness evaluation evidenced a 33% decrease in hospital-days for patients treated with sevelamer, with and without comorbidities compared to patients undergoing calcium binders treatment. Conclusion: Treatment with sevelamer was associated with a reduced risk of stroke in HD patients, with a clear saving on disease-related costs for the Italian National Healthcare System.

Exploring the Economic Benefits of Modafinil for Post-Stroke Fatigue in Australia: A Cost-Effectiveness Evaluation

2020 ◽  
Vol 29 (11) ◽  
pp. 105213
Author(s):  
Beata Bajorek ◽  
Lan Gao ◽  
Tom Lillicrap ◽  
Andrew Bivard ◽  
Carlos Garcia-Esperon ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Economic Benefits ◽  
Effectiveness Evaluation ◽  
Post Stroke
Sign in / Sign up

Export Citation Format

Share Document